{"id":"tiotropium-olodaterol","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":{"setId":"01e15aee-40e0-23f3-537f-c96dd63e2cb1","title":"STIOLTO RESPIMAT (TIOTROPIUM BROMIDE AND OLODATEROL) SPRAY, METERED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium blocks muscarinic receptors on airway smooth muscle, reducing bronchoconstriction, while olodaterol activates beta-2 adrenergic receptors to promote bronchodilation. Together, these complementary mechanisms provide sustained airway relaxation and improved airflow for patients with chronic obstructive pulmonary disease (COPD).","oneSentence":"Tiotropium and olodaterol is a combination of a long-acting muscarinic antagonist and a long-acting beta-2 agonist that work together to relax and open airways in the lungs.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:56.113Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT07267130","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT03663569","phase":"","title":"A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-08-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":4819},{"nctId":"NCT05393245","phase":"","title":"Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":19467},{"nctId":"NCT05402020","phase":"","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17018},{"nctId":"NCT04672941","phase":"","title":"Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1396},{"nctId":"NCT03954132","phase":"","title":"Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":469},{"nctId":"NCT05127304","phase":"","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":11316},{"nctId":"NCT05169424","phase":"","title":"A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9117},{"nctId":"NCT05927155","phase":"PHASE3","title":"Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2021-06-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT04231214","phase":"PHASE4","title":"Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects","status":"COMPLETED","sponsor":"Fraunhofer-Institute of Toxicology and Experimental Medicine","startDate":"2020-01-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":32},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT02812862","phase":"PHASE4","title":"Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2016-08","conditions":"COPD","enrollment":""},{"nctId":"NCT04249310","phase":"","title":"Early Intervention Efficacy in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-03-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6788},{"nctId":"NCT04011475","phase":"","title":"A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1617},{"nctId":"NCT03265145","phase":"PHASE4","title":"Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":714},{"nctId":"NCT02864407","phase":"","title":"Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3223},{"nctId":"NCT04223843","phase":"PHASE4","title":"A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-01-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":213},{"nctId":"NCT04926233","phase":"","title":"Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1371146},{"nctId":"NCT03979807","phase":"","title":"A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-06-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":11296},{"nctId":"NCT04138758","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"COPD","enrollment":42953},{"nctId":"NCT04184297","phase":"","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-11-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":27190},{"nctId":"NCT04402515","phase":"","title":"Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2021-10-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT04994574","phase":"NA","title":"Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT04011735","phase":"","title":"Re-usable Respimat® Soft MistTM Inhaler Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":262},{"nctId":"NCT03964220","phase":"","title":"Impact of Tiotropium Add-on Therapy in Patients With Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-15","conditions":"Asthma","enrollment":7857},{"nctId":"NCT02845752","phase":"PHASE4","title":"The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-03-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":14},{"nctId":"NCT03152149","phase":"PHASE4","title":"INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2017-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":80},{"nctId":"NCT03240575","phase":"PHASE4","title":"The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":302},{"nctId":"NCT02850978","phase":"","title":"Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1335},{"nctId":"NCT03673670","phase":"PHASE2","title":"Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2018-07-16","conditions":"COPD","enrollment":79},{"nctId":"NCT02927795","phase":"","title":"OTIVACTO Spain Non Interventional Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-04-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":257},{"nctId":"NCT02853123","phase":"PHASE4","title":"Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-09-22","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":106},{"nctId":"NCT03055988","phase":"PHASE4","title":"Cardiovascular Function in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76},{"nctId":"NCT02682862","phase":"PHASE4","title":"Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2016-07-11","conditions":"Asthma","enrollment":17},{"nctId":"NCT02629965","phase":"PHASE3","title":"Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-02-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":184},{"nctId":"NCT02720757","phase":"","title":"Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2016-08-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":132},{"nctId":"NCT02969317","phase":"PHASE1","title":"Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-02-24","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":12},{"nctId":"NCT03425617","phase":"PHASE4","title":"Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2017-01-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT02719639","phase":"","title":"OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":7443},{"nctId":"NCT02675517","phase":"","title":"Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-01-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1737},{"nctId":"NCT02683109","phase":"PHASE4","title":"Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":221},{"nctId":"NCT02799784","phase":"PHASE4","title":"An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-07-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT02296138","phase":"PHASE3","title":"Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":7903},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02173769","phase":"","title":"Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1845},{"nctId":"NCT02085161","phase":"PHASE3","title":"To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":304},{"nctId":"NCT01525615","phase":"PHASE3","title":"A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":404},{"nctId":"NCT01837927","phase":"PHASE3","title":"Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT02006732","phase":"PHASE3","title":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":809},{"nctId":"NCT02231177","phase":"PHASE1","title":"Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":47},{"nctId":"NCT01964352","phase":"PHASE3","title":"Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":813},{"nctId":"NCT01533935","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":291},{"nctId":"NCT01533922","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":295},{"nctId":"NCT00720499","phase":"PHASE2","title":"Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":141},{"nctId":"NCT00696020","phase":"PHASE2","title":"Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":360},{"nctId":"NCT01431274","phase":"PHASE3","title":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2624},{"nctId":"NCT01559116","phase":"PHASE3","title":"Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":219},{"nctId":"NCT02030535","phase":"PHASE2","title":"Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":53},{"nctId":"NCT01431287","phase":"PHASE3","title":"Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2539},{"nctId":"NCT01040403","phase":"PHASE2","title":"Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":233},{"nctId":"NCT01703845","phase":"PHASE1","title":"A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":32},{"nctId":"NCT01536262","phase":"PHASE3","title":"Japan Long-term Safety for Tiotropium Plus Olodaterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122},{"nctId":"NCT01696058","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1137},{"nctId":"NCT02259959","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT02259946","phase":"PHASE1","title":"Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-04","conditions":"Healthy","enrollment":48},{"nctId":"NCT01694771","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1134},{"nctId":"NCT01340209","phase":"PHASE3","title":"Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-04","conditions":"Asthma","enrollment":285},{"nctId":"NCT01040689","phase":"PHASE3","title":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":108},{"nctId":"NCT01040728","phase":"PHASE3","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Spiolto Respimat"],"phase":"marketed","status":"active","brandName":"Tiotropium & olodaterol","genericName":"Tiotropium & olodaterol","companyName":"University of Dundee","companyId":"university-of-dundee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium and olodaterol is a combination of a long-acting muscarinic antagonist and a long-acting beta-2 agonist that work together to relax and open airways in the lungs. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}